Graded exercise therapy for patients with chronic fatigue syndrome in secondary care - a benchmarking study.
Smakowski, Abigail, Adamson, James, Turner, Tracey et al. · Disability and rehabilitation · 2022 · DOI
Quick Summary
This study looked at how graded exercise therapy (gradually increasing physical activity) helped ME/CFS patients who were treated at a specialist clinic in London. Researchers tracked patients' fatigue levels, physical ability, and ability to work and socialize over the course of treatment. The results showed that patients improved significantly, with fatigue decreasing and daily functioning improving by the end of treatment.
Why It Matters
This study bridges the critical gap between clinical trials and real-world practice by demonstrating that GET does produce measurable improvements for ME/CFS patients in actual clinical settings. Understanding how treatment efficacy translates from controlled trials to everyday practice is essential for patients, clinicians, and healthcare systems making decisions about resource allocation and treatment options.
Observed Findings
Fatigue scores significantly decreased by session 4 (reduction of -5.18 points) and were maintained at follow-up (-4.73 points).
Work and social adjustment significantly improved by discharge and remained improved at follow-up (reduction of -4.97 points).
Physical functioning scores progressively improved throughout therapy, reaching significance at discharge with improvements maintained at follow-up (increase of 10.75 points on SF-36).
Effect sizes for all measured outcomes were notably smaller in routine clinical practice compared to published randomized controlled trials.
Inferred Conclusions
Graded exercise therapy produces clinically meaningful improvements in fatigue, physical functioning, and work/social adjustment for ME/CFS patients in specialist clinical practice.
The smaller effect sizes in routine practice compared to RCTs indicate that real-world treatment outcomes may be less robust than trial results, necessitating investigation into optimization strategies.
GET remains a viable treatment option for ME/CFS within specialist services, though outcomes variation between research and practice settings warrants further exploration.
Remaining Questions
What factors account for the smaller effect sizes observed in routine clinical practice compared to randomized controlled trials?
Which patient characteristics predict better or worse responses to GET in real-world clinical settings?
What This Study Does Not Prove
This study does not establish that GET is safe for all ME/CFS patients or determine which patient subgroups benefit most from treatment. The smaller effect sizes in routine practice compared to RCTs suggest that real-world outcomes may differ from trial conditions, and the study does not definitively explain why these differences exist. Additionally, without a control group, the study cannot distinguish between GET-specific benefits and natural recovery or other contextual factors.
Tags
Symptom:Fatigue
Method Flag:PEM Not DefinedWeak Case DefinitionNo Controls